Emil D Kakkis - Net Worth and Insider Trading
Emil D Kakkis Net Worth
The estimated net worth of Emil D Kakkis is at least $124 Million dollars as of 2024-12-26. Emil D Kakkis is the President & CEO of Ultragenyx Pharmaceutical Inc and owns about 2,760,317 shares of Ultragenyx Pharmaceutical Inc (RARE) stock worth over $121 Million. Emil D Kakkis is also the Chief Medical Officer of Biomarin Pharmaceutical Inc and owns about 39,621 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $3 Million. Details can be seen in Emil D Kakkis's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Emil D Kakkis has not made any transactions after 2024-12-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Emil D Kakkis
Emil D Kakkis Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Emil D Kakkis owns 2 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , and Biomarin Pharmaceutical Inc (BMRN) .
Click here to see the complete history of Emil D Kakkis’s form 4 insider trades.
Insider Ownership Summary of Emil D Kakkis
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2024-12-10 | director & 10 percent owner & President & CEO |
| BMRN | Biomarin Pharmaceutical Inc | 2009-03-02 | SVP & Business Operations |
Emil D Kakkis Latest Holdings Summary
Emil D Kakkis currently owns a total of 2 stocks. Among these stocks, Emil D Kakkis owns 2,760,317 shares of Ultragenyx Pharmaceutical Inc (RARE) as of December 10, 2024, with a value of $121 Million and a weighting of 97.85%. Emil D Kakkis also owns 39,621 shares of Biomarin Pharmaceutical Inc (BMRN) as of March 2, 2009, with a value of $3 Million and a weighting of 2.15%.
Latest Holdings of Emil D Kakkis
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2024-12-10 | 2,760,317 | 43.82 | 120,957,091 |
| BMRN | Biomarin Pharmaceutical Inc | 2009-03-02 | 39,621 | 67.02 | 2,655,399 |
Holding Weightings of Emil D Kakkis
Emil D Kakkis Form 4 Trading Tracker
According to the SEC Form 4 filings, Emil D Kakkis has made a total of 13 transactions in Ultragenyx Pharmaceutical Inc (RARE) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Ultragenyx Pharmaceutical Inc is the sale of 8,273 shares on December 10, 2024, which brought Emil D Kakkis around $413,650.
According to the SEC Form 4 filings, Emil D Kakkis has made a total of 0 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 7,897 shares on March 2, 2009, which brought Emil D Kakkis around $92,395.
Insider Trading History of Emil D Kakkis
- 1
Emil D Kakkis Trading Performance
GuruFocus tracks the stock performance after each of Emil D Kakkis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Emil D Kakkis is -14.31%. GuruFocus also compares Emil D Kakkis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Emil D Kakkis within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Emil D Kakkis's insider trading performs compared to the benchmark.
Performance of Emil D Kakkis
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.47 | | | | | |
| Relative Return to S&P 500(%) | -0.34 | | | | | |
Emil D Kakkis Ownership Network
Emil D Kakkis Owned Company Details
What does Ultragenyx Pharmaceutical Inc do?
Who are the key executives at Ultragenyx Pharmaceutical Inc?
Emil D Kakkis is the director & 10 percent owner & President & CEO of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include Chief Financial Officer Howard Horn , Controller and PAO Theodore Alan Huizenga , and EVP and General Counsel Karah Herdman Parschauer .
Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary
Over the past 18 months, Emil D Kakkis made 6 insider transaction in Ultragenyx Pharmaceutical Inc (RARE) with a net sale of 156,126. Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 3,565 shares made by Theodore Alan Huizenga , a net sale of 52,398 shares made by Thomas Richard Kassberg , and a net sale of 2,906 shares made by Sanders Corazon (corsee) D. .
In summary, during the past 3 months, insiders sold 15,738 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 15,738 shares. During the past 18 months, 264,892 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 264,892 shares.
Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ultragenyx Pharmaceutical Inc Insider Transactions
Emil D Kakkis Mailing Address
Above is the net worth, insider trading, and ownership report for Emil D Kakkis. You might contact Emil D Kakkis via mailing address: C/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato Ca 94949.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
